GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
Greenwich LifeSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$15.21+0.66 (+4.54%)
Close on Oct 19, 2026
- Market cap
- $222.39M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$5.72 (+60.27%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $222.39M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 71.35
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$22.47M
- EPS, diluted
- -$1.59
- Book value per share
- $0.21
- Diluted shares
- 15M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
-$21.87M
Net income
-$22.47M
EPS, diluted
-$1.59
Reported periodTrailing twelve months